Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00459069 · ClinicalTrials.gov registry record · Phase 1
The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma
A Phase 1 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00459069 is a Phase 1 study that has completed, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 18 participants.
The verdict
NCT00459069, a Phase 1 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The main purpose of this study is to test the safety of dendritic cell tumor fusion study vaccine and to determine the type and severity of any side effects associated with this study vaccine. Cancer cells have unique markers that distinguish them from normal cells of the body. These markers can potentially serve as targets for the immune system. Dendritic cells are normally found in small amounts in the body and are responsible for immune responses against "foreign" substances that enter the body. Animal studies have shown that these fused cells can stimulate powerful anti-tumor responses.
Interventions
- BIOLOGICAL Dendritic Cell Tumor Fusion Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2004-07 |
| Est. Completion | 2009-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00459069
The ClinicalTrials.gov registry entry for NCT00459069 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dendritic Cell Tumor Fusion Vaccine is the first listed.
NCT00459069 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00459069 about?
NCT00459069 is a clinical study titled "The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma". The main purpose of this study is to test the safety of dendritic cell tumor fusion study vaccine and to determine the type and severity of any side effects associated with this study vaccine. Cancer cells have unique markers that distinguish them from normal cells of the body. These markers can pot...
What is the current status of trial NCT00459069?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2004-07. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00459069?
The interventions under investigation include: Dendritic Cell Tumor Fusion Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00459069?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.